

Financial Forecast									
Personalized Treatment									
Breast Cancer (invasive)									
Year	# of New Diagnoses	HER2+	Best (95%)			Expected (65%)		Worst (50%)	
2020	267829	80349	76331	\$38,165,632.50	52227	\$26,113,327.50	40174	\$20,087,175.00	
2021	273607	82082	77978	\$38,988,997.50	53353	\$26,676,682.50	41041	\$20,520,525.00	
2022	279385	83816	79625	\$39,812,362.50	54480	\$27,240,037.50	41908	\$20,953,875.00	
2023	285163	85549	81271	\$40,635,727.50	55607	\$27,803,392.50	42774	\$21,387,225.00	
2024	290941	87282	82918	\$41,459,092.50	56733	\$28,366,747.50	43641	\$21,820,575.00	
2025	296719	89016	84565	\$42,282,457.50	57860	\$28,930,102.50	44508	\$22,253,925.00	
2026	302497	90749	86212	\$43,105,822.50	58987	\$29,493,457.50	45375	\$22,687,275.00	
2027	308275	92483	87858	\$43,929,187.50	60114	\$30,056,812.50	46241	\$23,120,625.00	
2028	314053	94216	89505	\$44,752,552.50	61240	\$30,620,167.50	47108	\$23,553,975.00	
2029	319831	95949	91152	\$45,575,917.50	62367	\$31,183,522.50	47975	\$23,987,325.00	
2030	325609	97683	92799	\$46,399,282.50	63494	\$31,746,877.50	48841	\$24,420,675.00	
Assumptions									
Growth rates based on extrapolated trends from historical data from 2013 - 2017									
Primary Indication: HER2+									
HER2+ accounts for approx 30% of invasive breast cancer									

Year	# of New Diagnoses	Other	Best		Expected		Worst	
2020	100000	70000	21000	\$10,500,000.00	17500	\$8,750,000.00	10500	\$5,250,000.00
2021	273607	191525	76610	\$38,304,980.00	67034	\$33,516,857.50	47881	\$23,940,612.50
2022	279385	195570	97785	\$48,892,375.00	78228	\$39,113,900.00	59884	\$29,942,115.00
2023	285163	199614	119768	\$59,884,230.00	89826	\$44,913,172.50	69865	\$34,932,467.50
2024	290941	203659	142561	\$71,280,545.00	101829	\$50,914,675.00	81463	\$40,731,740.00
2025	296719	207703	145392	\$72,696,155.00	103852	\$51,925,825.00	83081	\$41,540,660.00
2026	302497	211748	148224	\$74,111,765.00	105874	\$52,936,975.00	84699	\$42,349,580.00
2027	308275	215793	151055	\$75,527,375.00	107896	\$53,948,125.00	86317	\$43,158,500.00
2028	314053	219837	153886	\$76,942,985.00	109919	\$54,959,275.00	87935	\$43,967,420.00
2029	319831	223882	156717	\$78,358,595.00	111941	\$55,970,425.00	89553	\$44,776,340.00
2030	325609	227926	159548	\$79,774,205.00	113963	\$56,981,575.00	91171	\$45,585,260.00
Assumptions								
Best case: Starts with 30% market share and levels off at 70% after 5 years								
Expected case: Starts with 25% market share and levels off at 50% after 5 years								
Worst case: Starts with 15% market share and levels off at 40% after 5 years								
These assumptions apply to Breast Cancer (other), Colorectal, Brain cancers								